What South Korea’s pricing reforms mean for global pricing, access, and launch decisions
South Korea is implementing its most significant drug pricing overhaul in over a decade, with direct implications for how pharmaceutical manufacturers plan pricing, access, and launch sequencing across global markets.
The reforms expand dual pricing, tighten generic price controls, and introduce new incentives tied to innovation and supply stability, shifting how value is distributed across therapy areas.
To clarify what is changing and why it matters, Trinity analyzed South Korea’s current pricing and reimbursement system alongside the 2025–2026 reform package and its downstream commercial impact.
This advisory brief answers:
- How the Health Insurance Review and Assessment Service (HIRA) and the National Health Insurance Service (NHIS) will apply the new rules across assessment, price setting, and negotiation.
- How expanded dual pricing, deeper generic price cuts, and updated post-management timelines alter pricing dynamics for new drugs, off‑patent brands, biosimilars, and niche products.
- How these reforms may influence South Korea’s role as a reference market and affect global pricing corridors, launch sequencing, and portfolio decisions.
Complete the form below to access the advisory brief.
By submitting this form, creating an account, and/or using our website (or using our Services) you agree to our Privacy Policy. Information provided by you is stored in our database and may be used for sending you additional information about Trinity (including Trinity’s partners and affiliates) and our products and services. Such information may be transferred for this purpose to Trinity and affiliates in other countries. If you would like to opt out in the future, please email _compliance@trinitylifesciences.com.